Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We took interest in an article by Lazarus and colleagues published in a recent issue of JAMA Internal Medicine about proton pump inhibitors (PPIs).1 Proton pump inhibitors are common drugs worldwide that are essential for the treatments of gastroesophageal reflux disease, peptic ulcer, and dyspepsia. However, several recent studies reported that PPIs increased the risk of fractures, hypomagnesemia, myocardial infarction, and cryptogenic liver abscess.2- 5 In the article by Lazarus and colleagues,1 the authors examined the association of PPI use and the risk of kidney disease and drew the conclusions that PPI use was associated with a higher risk of incident chronic kidney disease and acute kidney injury.5 Here, we raise some points that should be noted.
Zhao P, Wei Z, Han J. Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease. JAMA Intern Med. 2016;176(6):867. doi:10.1001/jamainternmed.2016.1851